	US 12,458,655 B2
	Compositions for use in the prevention or treatment of necrotizing enterocolitis in infants or young children born by C-section
Per Torp Sangild, Copenhagen NV (DK)
Assigned to Societe des Produits Nestle S.A., Vevey (CH)
Filed by SOCIÉTÉ DES PRODUITS NESTLÉ S.A., Vevey (CH)
Filed on Feb. 3, 2021, as Appl. No. 17/166,547.
Application 17/166,547 is a division of application No. 15/036,855, granted, now 10,940,158, previously published as PCT/EP2014/074579, filed on Nov. 14, 2014.
Claims priority of application No. 13193058 (EP), filed on Nov. 15, 2013.
Prior Publication US 2021/0228602 A1, Jul. 29, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/702 (2006.01); A23L 33/00 (2016.01); A23L 33/125 (2016.01); A23L 33/135 (2016.01); A23L 33/21 (2016.01); A61K 35/741 (2015.01)

CPC A61K 31/702 (2013.01) [A23L 33/125 (2016.08); A23L 33/135 (2016.08); A23L 33/21 (2016.08); A23L 33/40 (2016.08); A61K 35/741 (2013.01); A23V 2002/00 (2013.01); A23V 2400/151 (2023.08); A23V 2400/165 (2023.08); A23V 2400/175 (2023.08); A23V 2400/245 (2023.08); A23V 2400/519 (2023.08); A23V 2400/529 (2023.08); A23V 2400/531 (2023.08); A23V 2400/533 (2023.08)]

14 Claims

1. A method for achieving at least one result selected from the group consisting of improving gut protection against microbial and pathogen overgrowth, promoting gut development and maturation, decreasing gut inflammation, and promoting enteral feeding tolerance, in an infant or young child born by C-section, the method comprising:

administering an effective amount of a composition comprising a mixture of human milk oligosaccharides to the infant or young child born by C-section,

the mixture comprising:

2′-fucosyllactose (2FL) that is 60 to 70 wt. % of the mixture of human milk oligosaccharides;

lacto-N-tetraose (LNT) and lacto-N-neotetraose (LNnT) that are 20 to 30 wt. % of the mixture of human milk oligosaccharides and in a ratio of LNT:LNnT between 2:1 and 1:1; and

6′ sialyllactose (6SL) that is 10 to 20 wt. % of the mixture of human milk oligosaccharides,

wherein the composition does not contain any galactooligosaccharides (GOS) other than the LNT and the LNnT.